title: Recombinant Mannheimia haemolytica serotype 1 outer membrane protein PlpE enhances commercial M. haemolytica vaccine-induced resistance against serotype 6 challenge.
abstract: Mannheimia haemolytica outer membrane protein PlpE, a major immunogenic outer membrane lipoprotein has identical sequences in serotypes 1 (S1) and S6. Recombinant outer membrane lipoprotein PlpE (rPLpE) from M. haemolytica S1 was added to commercial M. haemolytica S1 vaccines to determine if it would enhance vaccine-induced immunity against heterotypic M. haemolytica S6 challenge. Serum antibody responses to M. haemolytica whole cells, leukotoxin and rPlpE were measured. Experiment 1 consisted of four vaccine groups: controls, 100 microg rPlpE, M. haemolytica Bacterin-Toxoid (One Shot) and M. haemolytica Bacterin-Toxoid + 100 microg rPlpE. Vaccines were given on day 0. On day 21, calves were challenged transthoracically with M. haemolytica S6. Lung lesion scores and percentage lesion reduction were 6.3 +/- 2.0 for controls, 3.6 +/- 2.4 for rPlpE vaccinates (42.9% reduction), 3.4 +/- 1.5 for One Shot-vaccinates (46.0% reduction), and 2.4 +/- 1.4 for One Shot/rPlpE vaccinates (61.9% reduction). Experiment 2 consisted of four vaccine groups: controls, 100 microg rPlpE, M. haemolytica toxoid (Presponse), and M. haemolytica toxoid+100 microg rPlpE. On day 28, calves were challenged transthoracically with M. haemolytica S6. Lung lesion scores and percentage lesion reduction were 8.1 +/- 2.2 for controls, 4.4 +/- 4.7 for the rPlpE vaccinates (45.7% reduction), 4.8 +/- 2.2 for Presponse-vaccinates (40.7% reduction), and 2.0 +/- 1.2 for Presponse/rPlpE vaccinates (75.3% reduction). These results indicate that addition of rPlpE from M. haemolytica S1 can enhance commercial M. haemolytica vaccine-induced resistance against experimental challenge with M. haemolytica S6.
authors.affiliation: Department of Veterinary Pathobiology, 250 McElroy Hall, Center for Veterinary Health Sciences, Oklahoma State University, Stillwater, OK 74078-2007, USA. aconfer@cvm.okstate.edu
authors.forename: Anthony W
authors.initials: AW
authors.lastname: Confer
authors.forename: Sahlu
authors.initials: S
authors.lastname: Ayalew
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Panciera
authors.forename: Marie
authors.initials: M
authors.lastname: Montelongo
authors.forename: Joshua H
authors.initials: JH
authors.lastname: Wray
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D001428:Bacterial Vaccines / Q000276:immunology*; D002417:Cattle; D005098:Exotoxins / Q000276:immunology; D008074:Lipoproteins / Q000276:immunology*; D008168:Lung / Q000473:pathology; D016978:Mannheimia haemolytica / Q000145:classification / Q000276:immunology*; D008969:Molecular Sequence Data; D016871:Pasteurellaceae Infections / Q000517:prevention & control*; D011994:Recombinant Proteins / Q000276:immunology; D012703:Serotyping; D014614:Vaccines, Synthetic / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D005098:Exotoxins; D008074:Lipoproteins; C116100:PlpE protein, Pasteurella haemolytica; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; C018579:leukotoxin